[go: up one dir, main page]

US20160051626A1 - Compositions comprising complexes of proanthocyanidins with vegetable proteins - Google Patents

Compositions comprising complexes of proanthocyanidins with vegetable proteins Download PDF

Info

Publication number
US20160051626A1
US20160051626A1 US14/779,438 US201414779438A US2016051626A1 US 20160051626 A1 US20160051626 A1 US 20160051626A1 US 201414779438 A US201414779438 A US 201414779438A US 2016051626 A1 US2016051626 A1 US 2016051626A1
Authority
US
United States
Prior art keywords
complex
proanthocyanidins
protein
pea protein
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/779,438
Inventor
Miguel Angel Alonso
Marco Di Fulvio
Michele di Schiena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOVINTETHICAL PHARMA SA
Original Assignee
NOVINTETHICAL PHARMA SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOVINTETHICAL PHARMA SA filed Critical NOVINTETHICAL PHARMA SA
Assigned to NOVINTETHICAL PHARMA SA reassignment NOVINTETHICAL PHARMA SA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DI SCHIENA, MICHELE, ALONSO, Miguel Angel, Di Fulvio, Marco
Publication of US20160051626A1 publication Critical patent/US20160051626A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Definitions

  • the invention relates to complexes of proanthocyanidins with a vegetable protein and their use as active ingredients in compositions for the treatment of gastrointestinal disorders, in particular disorders caused by alterations of the intestinal epithelial tissue (simple non-ciliated cylindrical epithelium).
  • Diarrhoea is a symptom of many gastrointestinal disorders and is often incapacitating and dangerous, especially in children and the elderly. Acute diarrhoea is mainly caused by intestinal infections, but can also be due to the use of medicaments or radiotherapy and to other pathological conditions (diverticulitis, heavy-metal poisoning, intestinal ischaemia, allergies and intolerances).
  • Acute diarrhoea with an infectious cause is a serious problem in developing countries; it is believed to cause the death of at least 4 million children under 5 years old every year.
  • Chronic diarrhoea is generally due to irritable bowel syndrome, coeliac disease or inflammatory bowel diseases (Crohn's disease, ulcerative rectocolitis).
  • complexes known so far are effective and well tolerated, there is still a need for new complexes with improved characteristics in terms of efficacy, safety, organoleptic characteristics, stability, and compatibility with other ingredients of oral formulations.
  • complexes known and available to date are obtained from protein materials of animal origin, with the consequent safety problems associated with the possible transmission of diseases such as BSE, or allergies, which are particularly common in the case of proteins derived from milk and eggs.
  • Complexes with animal proteins can also give rise to ethical or religious problems in some patient populations.
  • the complex of proanthocyanidins with pea protein is particularly effective in the treatment of disorders caused by alterations of intestinal epithelial tissue (simple non-ciliated cylindrical epithelium).
  • the complex of the invention is advantageous in terms of safety, because it is practically devoid of liver toxicity, unlike the tannins already used to treat diarrhoea and other gastrointestinal disorders.
  • “Disorders caused by alterations of the intestinal epithelial tissue” means the inflammatory bowel diseases (Crohn and ulcerative colitis), celiac disease, enteric bacterial and parasitic infections (i.e. enteropathogenic Escherichia coli, Giardia lamblia infection, C. difficile infection, etc.), irritable bowel syndrome and various other diseases.
  • “Complex” means a chemical entity derived from the interaction between functional groups present on the protein and on the polyphenol structure. Said interactions, mainly of an ionic nature (such as hydrogen bonds), give the complex or adduct different physicochemical and biological properties from those of the components of the complex or their physical mixture.
  • Pisum protein means a powdered protein obtained by extraction from Pisum sativum seeds available on the market (http://en.wikipedia.org/wiki/Pea_protein).
  • proanthocyanidins refers to polyphenol compounds formed by the union of 2 to 8 catechin units. Proanthocyanidins are abundant in various plants, especially in grape skins and pips, lingonberries and bilberries, and some types of wood, such as quebracho wood. Proanthocyanidins, which belong to the family of condensed tannins, have a high level of antioxidant activity, and various studies have demonstrated their efficacy in reducing the blood pressure, reducing platelet aggregation and counteracting the progress or onset of disorders of the cardiovascular system. Proanthocyanidins also possess antibacterial, antiviral, anti-angiogenetic, antitumoral and chemopreventive properties. Various preparations of proanthocyanidins are available on the market, especially preparations of proanthocyanidins extracted from Vitis vinifera.
  • the pea protein and proanthocyanidin complex can be prepared by mixing an aqueous suspension of the protein with a solution of proanthocyanidins.
  • the pea protein is suspended in water, preferably in the ratio of 1:20 w/v.
  • a solution of proanthocyanidins obtained from grape pips is added to this suspension in the ratio of 1:10 w/v in water.
  • the ratio of pea protein to proanthocyanidins ranges between 1:0.1 and 1:2.5; it is preferably between 1:0.5 and 1:2; and more preferably of 1:1.5.
  • the pH is between 3 and 5, preferably between 3.5 and 4.5.
  • the temperature can vary within a wide range during the preparation of the complex: preferably between 10° C. and 50° C., and more preferably between 20° C. and 40° C.
  • the complex is isolated by known methods, such as filtration, centrifugation, spray-drying, freeze-drying etc.
  • the complex can be dried under vacuum, in an airstream, in fluid-bed dryers, etc., at a temperature preferably ranging between 20° C. and 40° C.
  • the complex thus obtained is highly stable to environmental humidity, even at temperatures exceeding ambient temperature.
  • the complex of the invention either alone or combined with other active ingredients and/or excipients, can be formulated in administration forms suitable for the recommended uses.
  • antibiotics include antibiotics, antimotility agents, steroidal and non-steroidal anti-inflammatories, compounds for the treatment of gastrointestinal bloating (simethicone and the like), mesalazine, sucralfate, natural and synthetic polysaccharides such as pectins, chitosan (animal or vegetable), hyaluronic acid, guar gum, xanthan gum, animal gelatins, cellulose and hemicellulose and derivatives such as hydroxypropylcellulose, carrageenans, carbomers, and crosslinking/polymerising compounds such as ferulic acid; and probiotics, such as Lactobacilli, Bifidobacteria, yeasts and the like.
  • probiotics such as Lactobacilli, Bifidobacteria, yeasts and the like.
  • the complex of the invention is useful for the treatment and prevention of gastrointestinal disorders and other disorders originating in the gastrointestinal system and transferred to other systems, such as the urogenital system.
  • the complex of the invention is also useful to prevent the proliferation of pathogens in the gastrointestinal system and their transfer to other systems of the human body through the tight intestinal junctions.
  • the complex of the invention is also useful to protect the intestinal mucosa against chemical or physical agents which can reduce the functionality and natural regeneration of the intestinal epithelium, and to reduce the paracellular flow of pathogens through the intestinal walls.
  • suitable forms of administration include capsules, tablets, solutions, suspensions, granules, gels, etc.
  • active ingredients with which the pea protein and proanthocyanidin complex can be combined include antibiotics, antimotility agents, anti-inflammatories, compounds for the treatment of gastrointestinal flatulence, prebiotics, probiotics, etc.
  • the pea protein and proanthocyanidin complex can be administered several times a day at doses ranging from 50 mg to 6000 mg/day.
  • the proanthocyanidin and pea protein complex in addition to being very effective and safe, is stable to hydrolysis and oxidation of the proanthocyanidin component.
  • proanthocyanidins (Grape Seed Dry Extract®, Indena Spa) is dissolved in 100 ml of purified water; the solution is prepared shortly before use, adjusting the pH from 6.7 to 4 with anhydrous citric acid, 20% sol. w/v in water, and heated to 30° C.; the dark red solution is added in portions to suspension A), still under stirring.
  • the complex in homogenous suspension that immediately forms is dark red, while the aqueous solution is reddish.
  • the suspension is kept under stirring for 3 hours, leaving the temperature to fall to 20° C.
  • the solid is washed with 100 ml of purified water acidified to pH 4 with a citric acid solution in 20 ml portions, aspirating thoroughly each time; the last wash is practically colourless.
  • the solid is stove-dried at 35-40° C. until it reaches a constant weight.
  • FIG. 1 shows the 1 H NMR spectrum of the complex characterised by broadened signals in the region at ⁇ 7.0, attributable to the aromatic protons of the proanthocyanidins.
  • the spectrum has a horizontal axis (T2) which relates to the resonance frequencies of the proton ( ⁇ or ppm), and a vertical axis (T1) which presents the diffusion parameter.
  • FIGS. 2 , 3 and 4 show the spectra recorded for proanthocyanidin obtained from Vitis vinifera , pea protein, and the complex of the invention, respectively.
  • HPLC gel-permeation assays were also performed. Isocratic elution was carried out with a mobile system formed by water, 0.1% formic acid and 3% methanol (flow rate of 1 mL/min., ELSD 60° C., 1.2 bar N2), stationary phase Tosohaas TSK G5000 PWXL 7.8 ⁇ 300 mm.
  • the chromatograms show the interaction between protein and proanthocyanidin.
  • the chromatogram of the pea protein mixture ( FIG. 5 ) clearly exhibits a prevalent peak at about 10 minutes, whereas the 95% black grape extract shows a prevalent peak at nearly 11 minutes, and a smaller peak at about 10 minutes ( FIG. 6 ).
  • the 50:50 complex shows a different chromatogram ( FIG. 7 ), characterised by a peak at retention times exceeding about 13 minutes, confirming the NMR observations.
  • the efficiency of the barrier and the chemical stability of the complex of the invention were evaluated by comparison with commercial gelatin tannate (Tasectan®) in the intestinal epithelium using the well-established predictive model of Caco-2 cells, a cell line of the intestinal epithelium deriving from a colorectal adenocarcinoma (ATCC HTB 37) (Cell. Biol. Toxicol. 2005, 21(1) 1-26).
  • TEER transepithelial electrical resistance
  • the permeability of the barrier was measured by determining the passage of the Lucifer Yellow dye (Le Ferrec et al., Altern Lab Anim. 2001 November-December; 29(6):649-68; Hidalgo et al., Gastroenterology. 1989 March; 96(3):736-49) after exposure to treatment with the compounds tested. This test was used to evaluate the integrity of the cell junctions in the presence of the substance tested. According to the technique described by Zucco et al., Altern. Lab Anim. 2005 December; 33(6):603-18, the cell monolayer was incubated with the compounds tested at the concentration of 5 mg/ml at two different pH values, 7.4 and 8.3. The TEER was evaluated at time 0 and after 4 hours, and the flow of the Lucifer Yellow dye was monitored for two hours after treatment with the products tested.
  • the results proved the ability of the products tested to act as film-forming agents able to restore the barrier function and reduce its permeability so as to protect the intestinal mucosa and the structure of the tight cell junctions.
  • the complex of the invention proved stable and active up to pH 8.3, unlike gelatin tannate, which is active at pH 7.4 but less active at pH 8.3, most likely due to hydrolysis of the tannins.
  • the proanthocyanidin complex is therefore more stable than the known gelatin tannate in the alkaline environment typical of the intestinal environment.
  • MPO Myeloperoxidase
  • MPO activity a marker of polymorphonuclear neutrophil primary granules, was determined in proximal jejunum tissues, according to a modified method of Bradley et al., (1982). After sacrifice, colonic samples were removed and snap frozen until the MPO activity determination. Briefly, the colonic segments were ground by using a Polytron, before being submitted to 3 cycles of freezing-thawing and centrifugation. Supernatants were discarded and pellets were resuspended in a detergent that releases MPO. These suspensions were sonicated on ice, and then centrifuged another time. Pellets were discarded and supernatants were assayed spectrophotometrically for MPO activity and protein measurements. Protein concentration was determined by the method of Lowry (Bio Rad Detergent Compatible Protein Assay, BIO Rad, Ivry-France), and MPO activity will be expressed as U MPO/g of protein.
  • the experimental protocol was performed on groups of 8 male Wistar rats (Janvier S. A., Le Genest St. Isle, France) weighing 200-225 g at the time of experiments.
  • the protocol consisted of a preventive oral administration of the complex of the invention at dose of 500 mg/kg or its vehicle (water) 2 h before ip injection of LPS from E. coli (1 mg/kg).
  • MPO Mucosal Myeloperoxidase Activity
  • jejunal mucosa MPO activity is very low (52 ⁇ 31 milliUnits/g. protein) and this tissular activity increased to 389 ⁇ 192 milliUnits/g. protein when measured 6 h. after LPS administration.
  • the complex of the invention affected significantly (P ⁇ 0.05) this LPS-induced increase in jejunal MPO.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a complex of pea protein and proanthocyanidins for use in the treatment of disorders caused by alterations of the intestinal epithelial tissue.

Description

  • The invention relates to complexes of proanthocyanidins with a vegetable protein and their use as active ingredients in compositions for the treatment of gastrointestinal disorders, in particular disorders caused by alterations of the intestinal epithelial tissue (simple non-ciliated cylindrical epithelium).
    • PRIOR ART
  • Diarrhoea is a symptom of many gastrointestinal disorders and is often incapacitating and dangerous, especially in children and the elderly. Acute diarrhoea is mainly caused by intestinal infections, but can also be due to the use of medicaments or radiotherapy and to other pathological conditions (diverticulitis, heavy-metal poisoning, intestinal ischaemia, allergies and intolerances).
  • Acute diarrhoea with an infectious cause is a serious problem in developing countries; it is believed to cause the death of at least 4 million children under 5 years old every year.
  • Chronic diarrhoea is generally due to irritable bowel syndrome, coeliac disease or inflammatory bowel diseases (Crohn's disease, ulcerative rectocolitis).
  • In view of their different etiologies, various treatment options are available, based on the administration of antibiotics/antibacterials, spasmolytics/anticholinergics, probiotics, or opioid receptor agonists. However, some of said treatments must be administered with great caution, because they do not act on the causal pathological process.
  • Complexes of tannins complexed with animal proteins and gelatins, in particular with gelatin of bovine origin, albumin, casein or ovalbumin, have been proposed for some time as effective remedies for gastrointestinal disorders.
  • For example, the use of said complexes in the treatment of the various forms of diarrhoea is disclosed in EP 1764105, EP 2526939, EP 2361623 and US 20090062191. Gelatin tannate has been available on the market for some time as a medical device for the treatment of acute diarrhoea.
  • Although the complexes known so far are effective and well tolerated, there is still a need for new complexes with improved characteristics in terms of efficacy, safety, organoleptic characteristics, stability, and compatibility with other ingredients of oral formulations. Moreover, the complexes known and available to date are obtained from protein materials of animal origin, with the consequent safety problems associated with the possible transmission of diseases such as BSE, or allergies, which are particularly common in the case of proteins derived from milk and eggs. Complexes with animal proteins can also give rise to ethical or religious problems in some patient populations.
  • There is consequently still a need for further treatments to replace or accompany those available today.
    • DESCRIPTION OF THE INVENTION
  • It has now surprisingly been found that the complex of proanthocyanidins with pea protein is particularly effective in the treatment of disorders caused by alterations of intestinal epithelial tissue (simple non-ciliated cylindrical epithelium). The complex of the invention is advantageous in terms of safety, because it is practically devoid of liver toxicity, unlike the tannins already used to treat diarrhoea and other gastrointestinal disorders.
  • “Disorders caused by alterations of the intestinal epithelial tissue” means the inflammatory bowel diseases (Crohn and ulcerative colitis), celiac disease, enteric bacterial and parasitic infections (i.e. enteropathogenic Escherichia coli, Giardia lamblia infection, C. difficile infection, etc.), irritable bowel syndrome and various other diseases.
  • “Complex” means a chemical entity derived from the interaction between functional groups present on the protein and on the polyphenol structure. Said interactions, mainly of an ionic nature (such as hydrogen bonds), give the complex or adduct different physicochemical and biological properties from those of the components of the complex or their physical mixture.
  • “Pea protein” means a powdered protein obtained by extraction from Pisum sativum seeds available on the market (http://en.wikipedia.org/wiki/Pea_protein).
  • One commercially available product, for example, is supplied by Dal Cin Gildo S.p.A. The product is in form of a yellowish powder with a characteristic odour, which is poorly soluble in water.
  • The term “proanthocyanidins” refers to polyphenol compounds formed by the union of 2 to 8 catechin units. Proanthocyanidins are abundant in various plants, especially in grape skins and pips, lingonberries and bilberries, and some types of wood, such as quebracho wood. Proanthocyanidins, which belong to the family of condensed tannins, have a high level of antioxidant activity, and various studies have demonstrated their efficacy in reducing the blood pressure, reducing platelet aggregation and counteracting the progress or onset of disorders of the cardiovascular system. Proanthocyanidins also possess antibacterial, antiviral, anti-angiogenetic, antitumoral and chemopreventive properties. Various preparations of proanthocyanidins are available on the market, especially preparations of proanthocyanidins extracted from Vitis vinifera.
  • The pea protein and proanthocyanidin complex can be prepared by mixing an aqueous suspension of the protein with a solution of proanthocyanidins. In particular, the pea protein is suspended in water, preferably in the ratio of 1:20 w/v. A solution of proanthocyanidins obtained from grape pips is added to this suspension in the ratio of 1:10 w/v in water.
  • The ratio of pea protein to proanthocyanidins ranges between 1:0.1 and 1:2.5; it is preferably between 1:0.5 and 1:2; and more preferably of 1:1.5.
  • It can be useful to acidify the suspension of pea protein in water, for example with citric acid, ascorbic acid or other acids, to improve the solubility of the protein; the pH is between 3 and 5, preferably between 3.5 and 4.5.
  • The temperature can vary within a wide range during the preparation of the complex: preferably between 10° C. and 50° C., and more preferably between 20° C. and 40° C.
  • The complex is isolated by known methods, such as filtration, centrifugation, spray-drying, freeze-drying etc.
  • The complex can be dried under vacuum, in an airstream, in fluid-bed dryers, etc., at a temperature preferably ranging between 20° C. and 40° C.
  • The complex thus obtained is highly stable to environmental humidity, even at temperatures exceeding ambient temperature. The complex of the invention, either alone or combined with other active ingredients and/or excipients, can be formulated in administration forms suitable for the recommended uses.
  • Other active ingredients which can be advantageously combined with the complexes of the invention include antibiotics, antimotility agents, steroidal and non-steroidal anti-inflammatories, compounds for the treatment of gastrointestinal bloating (simethicone and the like), mesalazine, sucralfate, natural and synthetic polysaccharides such as pectins, chitosan (animal or vegetable), hyaluronic acid, guar gum, xanthan gum, animal gelatins, cellulose and hemicellulose and derivatives such as hydroxypropylcellulose, carrageenans, carbomers, and crosslinking/polymerising compounds such as ferulic acid; and probiotics, such as Lactobacilli, Bifidobacteria, yeasts and the like.
  • The complex of the invention is useful for the treatment and prevention of gastrointestinal disorders and other disorders originating in the gastrointestinal system and transferred to other systems, such as the urogenital system. The complex of the invention is also useful to prevent the proliferation of pathogens in the gastrointestinal system and their transfer to other systems of the human body through the tight intestinal junctions. The complex of the invention is also useful to protect the intestinal mucosa against chemical or physical agents which can reduce the functionality and natural regeneration of the intestinal epithelium, and to reduce the paracellular flow of pathogens through the intestinal walls.
  • Examples of suitable forms of administration include capsules, tablets, solutions, suspensions, granules, gels, etc. Examples of other active ingredients with which the pea protein and proanthocyanidin complex can be combined include antibiotics, antimotility agents, anti-inflammatories, compounds for the treatment of gastrointestinal flatulence, prebiotics, probiotics, etc.
  • In view of its substantial absence of toxicity, the pea protein and proanthocyanidin complex can be administered several times a day at doses ranging from 50 mg to 6000 mg/day.
  • In particular, the proanthocyanidin and pea protein complex, in addition to being very effective and safe, is stable to hydrolysis and oxidation of the proanthocyanidin component.
  • The examples below illustrate the invention in greater detail.
    • EXAMPLE 1 Preparation of Complex
  • A) 10 g of pea protein (Dal Cin Gildo S.p.A.) is suspended in 200 g purified water. The pH of the suspension is adjusted from pH 6.3 to pH 4 with anhydrous citric acid, 20% sol. w/v in water. The suspension is left under stirring for 3 hours, and the temperature is increased to 30° C.
  • B) 10 g of proanthocyanidins (Grape Seed Dry Extract®, Indena Spa) is dissolved in 100 ml of purified water; the solution is prepared shortly before use, adjusting the pH from 6.7 to 4 with anhydrous citric acid, 20% sol. w/v in water, and heated to 30° C.; the dark red solution is added in portions to suspension A), still under stirring.
  • The complex in homogenous suspension that immediately forms is dark red, while the aqueous solution is reddish.
  • The suspension is kept under stirring for 3 hours, leaving the temperature to fall to 20° C.
  • Stirring is stopped and the suspension is left to stand for a further 8 hours, during which time it rapidly decants. The suspension is filtered through paper at low pressure.
  • The solid is washed with 100 ml of purified water acidified to pH 4 with a citric acid solution in 20 ml portions, aspirating thoroughly each time; the last wash is practically colourless. The solid is stove-dried at 35-40° C. until it reaches a constant weight.
  • Yield: 14.5 g; a brick-red, odourless, practically tasteless solid.
  • Analysis Data
  • FIG. 1 shows the 1H NMR spectrum of the complex characterised by broadened signals in the region at δ 7.0, attributable to the aromatic protons of the proanthocyanidins.
  • The formation of a complex deriving from the chemical interaction between the protein component and the polyphenol component is demonstrated by the 2D DOSY (Diffusion Ordered Spectroscopy) NMR technique.
  • The spectrum has a horizontal axis (T2) which relates to the resonance frequencies of the proton (δ or ppm), and a vertical axis (T1) which presents the diffusion parameter.
  • FIGS. 2, 3 and 4 show the spectra recorded for proanthocyanidin obtained from Vitis vinifera, pea protein, and the complex of the invention, respectively.
  • Signals distributed between the values in log(m2/s) (T1) of −9.2 and −10.5 can be observed in the spectrum of proanthocyanidin obtained from Vitis vinifera.
  • Conversely, the 2D DOSY spectrum of pea protein presents signals with T1 values between −8.7 and −10.1. The complex has a different behaviour from the preceding ones, with signals ranging between −9.1 and 10.0.
  • This indicates that an interaction exists between the species to form a different situation from the components. It is suggested that the interaction between protein and proanthocyanidin causes modifications to the protein structure, making it more compact and consequently obtaining a different diffusion coefficient.
  • HPLC gel-permeation assays were also performed. Isocratic elution was carried out with a mobile system formed by water, 0.1% formic acid and 3% methanol (flow rate of 1 mL/min., ELSD 60° C., 1.2 bar N2), stationary phase Tosohaas TSK G5000 PWXL 7.8×300 mm.
  • The chromatograms show the interaction between protein and proanthocyanidin. In particular, the chromatogram of the pea protein mixture (FIG. 5) clearly exhibits a prevalent peak at about 10 minutes, whereas the 95% black grape extract shows a prevalent peak at nearly 11 minutes, and a smaller peak at about 10 minutes (FIG. 6).
  • The 50:50 complex shows a different chromatogram (FIG. 7), characterised by a peak at retention times exceeding about 13 minutes, confirming the NMR observations.
    • EXAMPLE 2 Biological Tests in Vitro
  • The efficiency of the barrier and the chemical stability of the complex of the invention were evaluated by comparison with commercial gelatin tannate (Tasectan®) in the intestinal epithelium using the well-established predictive model of Caco-2 cells, a cell line of the intestinal epithelium deriving from a colorectal adenocarcinoma (ATCC HTB 37) (Cell. Biol. Toxicol. 2005, 21(1) 1-26).
  • The paracellular flow and the barrier permeability of the compounds tested were determined.
  • Paracellular flow was determined by measuring the transepithelial electrical resistance (TEER), which provides a direct measurement of the barrier function and is a further parameter of the integrity of the barrier at the tight junctions.
  • The permeability of the barrier was measured by determining the passage of the Lucifer Yellow dye (Le Ferrec et al., Altern Lab Anim. 2001 November-December; 29(6):649-68; Hidalgo et al., Gastroenterology. 1989 March; 96(3):736-49) after exposure to treatment with the compounds tested. This test was used to evaluate the integrity of the cell junctions in the presence of the substance tested. According to the technique described by Zucco et al., Altern. Lab Anim. 2005 December; 33(6):603-18, the cell monolayer was incubated with the compounds tested at the concentration of 5 mg/ml at two different pH values, 7.4 and 8.3. The TEER was evaluated at time 0 and after 4 hours, and the flow of the Lucifer Yellow dye was monitored for two hours after treatment with the products tested.
  • The results proved the ability of the products tested to act as film-forming agents able to restore the barrier function and reduce its permeability so as to protect the intestinal mucosa and the structure of the tight cell junctions. The complex of the invention proved stable and active up to pH 8.3, unlike gelatin tannate, which is active at pH 7.4 but less active at pH 8.3, most likely due to hydrolysis of the tannins.
  • The proanthocyanidin complex is therefore more stable than the known gelatin tannate in the alkaline environment typical of the intestinal environment.
    • Example 3 Biological Tests in Vivo
  • The activity of the complex of proanthocyanidin obtained from Vitis vinifera and pea protein on the altered intestinal permeability and intestinal inflammation induced by lipopolysaccharide (LPS) was evaluated.
  • Groups of 8 male Wistar rats (200-225 g) have been used. After on overnight fast, the animals were injected intraperitoneally (IP) with 250 μL of sterile saline (NaCl 0.9%) containing or not (control) 1 mg/kg of lipopolysaccharide (LPS) from E. Coli. This dose has been previously shown to alter intestinal permeability and to release pro-inflammatory cytokines in the mucosa (TNFα, IL-1β, IFNγ (Moriez R,. Am J Pathol. 2005; 167(4):1071-9). Six hours later, the animals have been sacrificed and strips of jejunum were used for evaluation of TEER and FITC-dextran paracellular permeability. Other segments were also collected for other parameters of mucosal inflammation (myeloperoxidase-MPO).
  • Six hours after LPS administration, the rats were sacrificed by cervical dislocation and the proximal part of the jejunum was removed. Jejunal strips were mounted in Using-type chambers (Physiologic Instruments, San Diego, Calif.). Both sides of each colonic layer will be bathed in Krebs-Henseleit buffer (Sigma) and oxygenated on a maintained temperature of 37° C. After 15 min for equilibrium, TEER was measured and 1 ml of buffer solution was replaced with physiological saline and 500 μl of FITC-dextran (4000 MW, 0.022 g/ml, Sigma) on mucosal side of each chamber. The fluorescence intensity generated was then measured 1 hour later.
  • Myeloperoxidase (MPO) Activity
  • MPO activity, a marker of polymorphonuclear neutrophil primary granules, was determined in proximal jejunum tissues, according to a modified method of Bradley et al., (1982). After sacrifice, colonic samples were removed and snap frozen until the MPO activity determination. Briefly, the colonic segments were ground by using a Polytron, before being submitted to 3 cycles of freezing-thawing and centrifugation. Supernatants were discarded and pellets were resuspended in a detergent that releases MPO. These suspensions were sonicated on ice, and then centrifuged another time. Pellets were discarded and supernatants were assayed spectrophotometrically for MPO activity and protein measurements. Protein concentration was determined by the method of Lowry (Bio Rad Detergent Compatible Protein Assay, BIO Rad, Ivry-France), and MPO activity will be expressed as U MPO/g of protein.
  • The experimental protocol was performed on groups of 8 male Wistar rats (Janvier S. A., Le Genest St. Isle, France) weighing 200-225 g at the time of experiments. The protocol consisted of a preventive oral administration of the complex of the invention at dose of 500 mg/kg or its vehicle (water) 2 h before ip injection of LPS from E. coli (1 mg/kg). These experiments were finally conducted on 3 separate groups of animals:
      • 1 group as the control group (vehicle)−no LPS
      • 1 group as the positive group (vehicle+LPS)
      • 1 group compound CL-8 (500 mg/kg+LPS)
  • Intestinal Permeability:
  • Six hours after IP treatment with LPS, using chamber measurements jejunal permeability to FITC-dextran indicated that there was a huge increase in permeability to macromolecules, this increase was also significantly (P≦0.05) reduced by the compound of the invention (500 mg/kgPO) by 64.6%.
  • The results are reported in FIG. 8 showing the influence of single oral treatment on LPS-induced increased jejunal permeability in rats (mean±SEM permeability n=2×8).
  • Mucosal Myeloperoxidase Activity (MPO):
  • In basal conditions, the jejunal mucosa MPO activity is very low (52±31 milliUnits/g. protein) and this tissular activity increased to 389±192 milliUnits/g. protein when measured 6 h. after LPS administration. The complex of the invention affected significantly (P≦0.05) this LPS-induced increase in jejunal MPO.
  • The results are reported in FIG. 9 showing the influence of single oral treatment on mucosal MPO activity in rats (mean±SEM MPO n=8)).
    • Example 4 Pharmaceutical Formulation
  • Composition for the treatment of diarrhoea, 4 g single-dose sachet
  •
    Complex of pea protein with proanthocyanidins 0.500 g
    (example 1)
    Inulin 1.500 g
    Maltodextrin 1.675 g
    Ascorbic acid 0.100 g
    Monoglyceride (Rimulsoft super (V) 0.150 g
    Silicon dioxide (Aerosil 200) 0.020 g
    Stevioside (Stevia) 0.015 g
    E160a colouring (betacarotene) 0.025 g

Claims (8)

1. (canceled)
2. Method as claimed in claim 5, wherein the proanthocyanidins are extracted from Vitis vinifera, lingonberries or bilberries, or quebracho wood.
3. Method as claimed in claim 2, wherein the proanthocyanidins are extracted from Vitis vinifera.
4. Method as claimed in claim 5, wherein the ratio between pea protein and proanthocyanidins is between 1:0.1 and 1:2.5.
5. Method of treating disorders caused by alterations of the intestinal epithelial tissue in a subject in need thereof with a complex comprising pea protein and proanthocyanidins, said method comprising:
administering to said subject in need thereof an effective amount of said complex; and
treating said subject.
6. Method as claimed in claim 5, wherein the disorder is diarrhoea.
7. Method as claimed in claim 5 wherein said complex is, in admixture with suitable carriers.
8. Method as claimed in claim 7, wherein said complex further comprises other active ingredients selected from antibiotics, antimotility agents, steroidal and non-steroidal anti-inflammatories, compounds for the treatment of gastrointestinal bloating, mesalazine, sucralfate, pectins, chitosan, hyaluronic acid, guar gum, xanthan gum, animal gelatins, plant proteins, cellulose and hemicellulose, hydroxypropyl-cellulose, carrageenans, carbomers, ferulic acid, probiotics, gelatin tannate and electrolytes.
US14/779,438 2013-03-28 2014-03-27 Compositions comprising complexes of proanthocyanidins with vegetable proteins Abandoned US20160051626A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2013A000476 2013-03-28
IT000476A ITMI20130476A1 (en) 2013-03-28 2013-03-28 COMPOSITIONS FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERS BASED ON TANNIN COMPLEXES WITH PROTEINS
PCT/EP2014/056138 WO2014154796A1 (en) 2013-03-28 2014-03-27 Compositions comprising complexes of proanthocyanidins with vegetable proteins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/056138 A-371-Of-International WO2014154796A1 (en) 2013-03-28 2014-03-27 Compositions comprising complexes of proanthocyanidins with vegetable proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/380,732 Continuation US9901613B2 (en) 2013-03-28 2016-12-15 Compositions comprising complexes of proanthocyanidins with pea proteins

Publications (1)

Publication Number Publication Date
US20160051626A1 true US20160051626A1 (en) 2016-02-25

Family

ID=48227425

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/779,438 Abandoned US20160051626A1 (en) 2013-03-28 2014-03-27 Compositions comprising complexes of proanthocyanidins with vegetable proteins
US15/380,732 Active US9901613B2 (en) 2013-03-28 2016-12-15 Compositions comprising complexes of proanthocyanidins with pea proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/380,732 Active US9901613B2 (en) 2013-03-28 2016-12-15 Compositions comprising complexes of proanthocyanidins with pea proteins

Country Status (6)

Country Link
US (2) US20160051626A1 (en)
EP (1) EP2978436B1 (en)
CA (1) CA2907918C (en)
ES (1) ES2622435T3 (en)
IT (1) ITMI20130476A1 (en)
WO (1) WO2014154796A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021087401A (en) * 2019-12-05 2021-06-10 中野Ｂｃ株式会社 Food product and method for producing the same, and agent
CN113812511A (en) * 2021-09-22 2021-12-21 西北农林科技大学 A method for improving the functional properties of pea protein
CN115474647A (en) * 2022-09-06 2022-12-16 江南大学 Highland barley protein-polyphenol compound and preparation method and application thereof
CN115736177A (en) * 2022-11-24 2023-03-07 江南大学 Application of highland barley gluten/procyanidine compound in highland barley raw wet noodles
CN115886259A (en) * 2022-12-30 2023-04-04 天津市尖峰天然产物研究开发有限公司 Anthocyanin-protein complex and preparation method and application thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020095238A1 (en) * 2018-11-07 2020-05-14 Massey University Flavonoid delivery system
IT201900025246A1 (en) 2019-12-23 2021-06-23 Devintec Sagl TOPICAL COMPOSITIONS INCLUDING VEGETABLE PROTEINS AND POLYPHENOLS

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004017979A2 (en) * 2002-08-16 2004-03-04 Finzelberg Gmbh & Co. Kg Medicament, food supplement, and fodder additive
US20060210697A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Infant formula composition
EP1911457A1 (en) * 2006-10-12 2008-04-16 N.V. Nutricia Composition to treat or prevent gastrointestinal infection
US20090117056A1 (en) * 2006-09-27 2009-05-07 Little Calumet Holdings, Llc Probiotic oral dosage forms
US20090148397A1 (en) * 1996-10-16 2009-06-11 Edward James Rozhon Compositions and Methods of Treatment With Proanthocyanidin Polymer Antidiarrheal Compositions
WO2010114864A1 (en) * 2009-04-01 2010-10-07 Little Calumet Holdings, Llc Probiotic oral dosage forms
US20120015078A1 (en) * 2009-03-02 2012-01-19 Roquette Freres Vegetable milk granulated powder, process for producing vegetable milk, and uses thereof
US20130203663A1 (en) * 2010-06-28 2013-08-08 Nestec S.A. Tube feed formulations and methods for using same
US20140037603A1 (en) * 2011-04-12 2014-02-06 Doug Bolster Nutritional compositions including branched chain fatty acids for improving gut barrier function
US20140134206A1 (en) * 2011-04-01 2014-05-15 University Of Florida Research Foundation, Inc. Inflammation and immunity treatments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758984B1 (en) * 1997-02-03 1999-04-16 Serobiologiques Lab Sa ACTIVE SYNERGISTIC COMPLEX AND COSMETIC AND / OR PHARMACEUTICAL PRODUCT COMPRISING THIS COMPLEX
US20020001651A1 (en) * 2000-01-24 2002-01-03 Norris Leslie Marie Method of altering and improving taste characteristics of edible consumables with monomeric or oligomeric polyphenolic compounds
EP1764105A1 (en) 2005-09-20 2007-03-21 Rentschler Arzneimittel GmbH Use of tanning agents for the treatment of diarrhoea induced by chemotherapy
US20090062191A1 (en) * 2007-08-29 2009-03-05 Kiel Laboratories, Inc. Composition for maintaining gastrointestinal homeostasis
EP2361623A1 (en) 2010-02-09 2011-08-31 Novintethical Pharma, SAGL Composition comprising a polyphenol salt and corresponding use
ITMI20110934A1 (en) * 2011-05-24 2012-11-25 Cohen Miguel Angel Alonso GELATINE TANNATE AND ITS ASSOCIATIONS FOR USE IN THE TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISEASES

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090148397A1 (en) * 1996-10-16 2009-06-11 Edward James Rozhon Compositions and Methods of Treatment With Proanthocyanidin Polymer Antidiarrheal Compositions
WO2004017979A2 (en) * 2002-08-16 2004-03-04 Finzelberg Gmbh & Co. Kg Medicament, food supplement, and fodder additive
US20060210697A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Infant formula composition
US20090117056A1 (en) * 2006-09-27 2009-05-07 Little Calumet Holdings, Llc Probiotic oral dosage forms
EP1911457A1 (en) * 2006-10-12 2008-04-16 N.V. Nutricia Composition to treat or prevent gastrointestinal infection
US20120015078A1 (en) * 2009-03-02 2012-01-19 Roquette Freres Vegetable milk granulated powder, process for producing vegetable milk, and uses thereof
WO2010114864A1 (en) * 2009-04-01 2010-10-07 Little Calumet Holdings, Llc Probiotic oral dosage forms
US20130203663A1 (en) * 2010-06-28 2013-08-08 Nestec S.A. Tube feed formulations and methods for using same
US20140134206A1 (en) * 2011-04-01 2014-05-15 University Of Florida Research Foundation, Inc. Inflammation and immunity treatments
US20140037603A1 (en) * 2011-04-12 2014-02-06 Doug Bolster Nutritional compositions including branched chain fatty acids for improving gut barrier function

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021087401A (en) * 2019-12-05 2021-06-10 中野Ｂｃ株式会社 Food product and method for producing the same, and agent
JP7161210B2 (en) 2019-12-05 2022-10-26 中野Ｂｃ株式会社 Food and its manufacturing method and agent
CN113812511A (en) * 2021-09-22 2021-12-21 西北农林科技大学 A method for improving the functional properties of pea protein
CN115474647A (en) * 2022-09-06 2022-12-16 江南大学 Highland barley protein-polyphenol compound and preparation method and application thereof
CN115736177A (en) * 2022-11-24 2023-03-07 江南大学 Application of highland barley gluten/procyanidine compound in highland barley raw wet noodles
CN115886259A (en) * 2022-12-30 2023-04-04 天津市尖峰天然产物研究开发有限公司 Anthocyanin-protein complex and preparation method and application thereof

Also Published As

Publication number Publication date
CA2907918A1 (en) 2014-10-02
US20170095528A1 (en) 2017-04-06
US9901613B2 (en) 2018-02-27
ES2622435T3 (en) 2017-07-06
EP2978436A1 (en) 2016-02-03
WO2014154796A1 (en) 2014-10-02
EP2978436B1 (en) 2017-02-01
ITMI20130476A1 (en) 2014-09-29
CA2907918C (en) 2020-07-07

Similar Documents

Publication Publication Date Title
US9901613B2 (en) Compositions comprising complexes of proanthocyanidins with pea proteins
Yang et al. Gut microbiota-dependent catabolites of tryptophan play a predominant role in the protective effects of turmeric polysaccharides against DSS-induced ulcerative colitis
US10449249B2 (en) Polysaccharide suitable to modulate immune response
DK2701714T3 (en) PROCEDURE FOR ISOLATING POLYSACCHARIDES
CA2945631C (en) Compositions based on xyloglucan and proteins for the treatment of intestinal disorders
US8367126B2 (en) Berry preparations and extracts
KR102349970B1 (en) Polysaccharide from Celosia cristata flower extract, method of extracting the same and immunostimulating composition comprising the same
US7964223B2 (en) Berry preparations and extracts
US12076356B2 (en) Composition comprising Molokhia extract as active ingredient for improving gut microbiome or for alleviating, preventing, or treating intestinal inflammation, leaky gut syndrome, obesity, or metabolic disease
WO2018116238A1 (en) Composition for use in the treatment of disorders of the urogenital apparatus
KR102813948B1 (en) Boysenberry, apple, and blackcurrant compositions and methods for their preparation and use
KR20210112146A (en) Composition for preventing, improving or treating pulmonary fibrosis comprising complex of anthocyanin and anionic polysaccharide
CN1863524B (en) vacuolating toxin neutralizer
KR102075799B1 (en) Pharmaceutical composition comprising the extract of an unripe apple as an effective component for prevention or treatment of thrombosis and health functional food comprising the same
KR101167677B1 (en) A composition comprising extracts of Elaeocarpus petiolatus for prevention and treatment of inflammatory diseases
US20060029690A1 (en) Buckwheat compound and method of obtaining the same for treatment of hyperglycemia
KR20190058394A (en) Antimicrobial, antiparasite, antiviral and antioxidant compositions of fish comprising Rhus verniciflua lignum extract
WO2024252335A1 (en) New association of active ingredients of plant origin, compositions containing it and use thereof in therapy
Zidan et al. A Comprehensive Review of the Potential Use of Green Tea Polyphenols in the Management of COVID-19
KR101814175B1 (en) Antimicrobial, antiparasite, antiviral and antioxidant compositions of fish comprising Rhus verniciflua lignum extract
Mumper et al. Berry preparation and extracts
EP4489768A1 (en) Aronia extracts and uses thereof
JP5772678B2 (en) Cosmetic and functional food materials with water retention, water absorption and hyaluronidase inhibitory activity
CN113730590A (en) A microcapsule decoction piece for preventing and improving Alzheimer disease and dementia, and its preparation method
KR20180092812A (en) Antimicrobial, antiparasite, antiviral and antioxidant compositions of fish comprising Rhus verniciflua lignum extract

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVINTETHICAL PHARMA SA, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ALONSO, MIGUEL ANGEL;DI FULVIO, MARCO;DI SCHIENA, MICHELE;SIGNING DATES FROM 20150926 TO 20151006;REEL/FRAME:036756/0972

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION